| 000 | 01899 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515053859.0 | ||
| 264 | 0 | _c20070822 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a1078-0998 | ||
| 024 | 7 |
_a10.1002/ibd.20100 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGao, Qiang | |
| 245 | 0 | 0 |
_aInfliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. _h[electronic resource] |
| 260 |
_bInflammatory bowel diseases _cJun 2007 |
||
| 300 |
_a693-702 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aCrohn Disease _xblood |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGene Expression _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 2 _xblood |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 9 _xblood |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutrophils _xenzymology |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMeijer, Martin J W | |
| 700 | 1 | _aSchlüter, Ulrike G | |
| 700 | 1 | _avan Hogezand, Ruud A | |
| 700 | 1 | _avan der Zon, Johanna M | |
| 700 | 1 | _avan den Berg, Marlies | |
| 700 | 1 | _avan Duijn, Wim | |
| 700 | 1 | _aLamers, Cornelis B H W | |
| 700 | 1 | _aVerspaget, Hein W | |
| 773 | 0 |
_tInflammatory bowel diseases _gvol. 13 _gno. 6 _gp. 693-702 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ibd.20100 _zAvailable from publisher's website |
| 999 |
_c16806455 _d16806455 |
||